The following is a summary of the GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript:

Financial Performance:

• GeoVax reported a net loss of $5.9 million for Q1 2024, or $2.47 per share, compared to a loss of $4 million in 2023, or $2.30 per share, primarily driven by the clinical trial programs for CM04S1 and Gedeptin.

• Research and development expenses were $4.4 million, up $1.6 million or 57% compared to 2023.

• Q1 2024 general and administrative expenses remained relatively unchanged at $1.5 million.

• Cash balances at the end of the first quarter stood at $769,000, down $5.7 million from the end of 2023 due to operating activities.

Business Progress:

• GeoVax has made significant progress with its two Phase 2 products, Gedeptin and GEO-CM04S1, with the former being in trial phase for cancer patients.

• For 2024, GeoVax will continue to focus on Gedeptin and CM04S1, targeting underserved patient populations.

• The company expects to report final results for the Gedeptin trial in the first half of 2024.

• The company anticipates delivering results from Phase 2 programs for their next-generation COVID-19 vaccine, CM04S1.

• There are advanced discussions regarding Project NextGen with BARDA and potential evaluation of Gedeptin as combination therapy with immune checkpoint inhibitors.

• CM04S1 is undergoing three Phase 2 trials, two of which are aimed at high-risk populations.

• Final results from the vaccine clinical trials are expected in Q4 2024, and the company is planning to raise capital in the near future.

More details: GeoVax Labs IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.